CollPlant Biotechnologies

CollPlant was notified by Nasdaq that its stock closed below $1.00 for 30 consecutive trading days, violating Rule 5550(a)(2). The share currently trades at $0.71; Nasdaq has given until September 21, 2026 to regain compliance by achieving at least ten consecutive closing prices ≥ $1.00. Otherwise, a second 180-day period could be granted under certain conditions, for example after a reverse stock split. CollPlant says it will monitor the share price and consider options; analysts’ price target is $11.12 and one analysis indicates the stock is undervalued. » Plus sur de.investing.com

CollPlant has introduced BioFlex, a ready-to-use bio-ink kit based on recombinant human collagen (including Collink.3D 50) for high-resolution DLP‑3D bioprinting. The system is aimed at academic and industrial users for producing tissue models, tissue engineering and regenerative medicine and is intended to reduce formulation effort and development times. CollPlant describes BioFlex as an animal-free alternative to conventional systems; the company produces rhCollagen using plant-based genetic engineering. Financial notes: CollPlant has reported prior losses, requires additional capital and its stock fell sharply last year, while analyses point to possible undervaluation and solid short-term liquidity. » Plus sur de.investing.com

CollPlant Biotechnologies has scheduled its ordinary and extraordinary shareholders' meetings for December 31, 2025, at 10:00 a.m. in Tel Aviv. The company published a notice and a proxy statement with information on voting procedures and a voting card for non‑attendance. No details on the agenda or specific proposals were disclosed; the announcement is based on a filing submitted to the SEC. » Plus sur de.investing.com